StockMarketWire.com - Brain health company IXICO has won a contract worth $1.2m with a top 15 global pharmaceutical company for advanced imaging clinical trial services in a rare neurodegenerative disease.

The project is for a phase IIa clinical study of patients in the early stages of progressive supranuclear palsy to develop a first-in-class therapy that could prevent further degeneration.

IXICO's TrialTracker and Assessa digital platforms will be used to collect and analyse MRI data from specialist imaging centres across Europe and North America.

The study is expected to complete in 2019 with the potential to be extended further.

At 1:00pm: [LON:IXI] IXICO plc share price was +4.5p at 28p



Story provided by StockMarketWire.com